HEARD (long term) study – Histology of the Esophagus in Acid-Related Disease
Study identifier:D9612L00078
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An open-label, parallel-group, multi-centre study to determine the effect of treatment with esomeprazole for six months on histological markers of esophageal epithelial acid-related disease in patients with upper GI symptoms.
Medical condition
Gastroesophageal Reflux
Phase
Phase 3
Healthy volunteers
No
Study drug
Esomeprazole
Sex
All
Actual Enrollment
350
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Apr 2005
Primary Completion Date: 01 Jun 2007
Study Completion Date: 01 Jun 2007
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca Canada Medical Director
AstraZeneca
